Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 16/20 | 0.56 |
| ▸ | BACE2 | Q9Y5Z0 | 9/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2622848 | 1.00 | BACE1 (0.56) | BACE1BACE2KCNH2CTSD | |
| SCHEMBL2928070 | 1.00 | BACE1 (0.56) | BACE1BACE2KCNH2CTSD | |
| SCHEMBL2620000 | 0.91 | BACE1 (0.49) | BACE1BACE2KCNH2CTSD | |
| SCHEMBL11886479 | 0.89 | BACE1 (0.45) | BACE1BACE2 | |
| SCHEMBL11025468 | 0.88 | BACE1 (0.56) | BACE1BACE2CTSD | |
| SCHEMBL2933883 | 0.88 | BACE1 (0.46) | BACE1BACE2KCNH2CTSD | |
| SCHEMBL2619886 | 0.88 | BACE1 (0.46) | BACE1BACE2KCNH2CTSD | |
| SCHEMBL15835728 | 0.88 | BACE1 (0.48) | BACE1BACE2KCNH2CTSD | |
| Hydrochloric Acid SCHEMBL11025691 | 0.87 | BACE1 (0.55) | BACE1BACE2CTSD | |
| SCHEMBL11950544 | 0.86 | BACE1 (0.53) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2665716-B1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2017-03-08 | — | — | EP | disclosed |
| US-8962858-B2 | Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-02-24 | — | — | US | disclosed |
| US-20140309429-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2014-10-16 | — | — | US | disclosed |
| US-8802871-B2 | Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-08-12 | — | — | US | disclosed |
| US-20130197244-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-01 | — | — | US | disclosed |
| US-20120190848-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| WO-2009091016-A1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309429-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF FUSED AMINODIHYDROTHIAZINE DERIVATIVES | APP, BACE1, BACE2 | BACE1 2/4885BACE2 3/4885KCNH2 3778/4885 |
| US-20130197244-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF FUSED AMINODIHYDROTHIAZINE DERIVATIVES | APP, BACE1, BACE2 | BACE1 2/4885BACE2 3/4885KCNH2 3778/4885 |
| US-20120190848-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF FUSED AMINODIHYDROTHIAZINE DERIVATIVES | APP, BACE1, BACE2 | BACE1 2/4885BACE2 3/4885KCNH2 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.